For pharma stakeholders, this head-to-head competition highlights opportunities in market differentiation, patient segmentation, and clinical positioning
On the eraser side, FTO has emerged as a radiosensitization target: genetic and pharmacologic FTO blockade increased DNA damage (reduced RAD51 foci, impaired HR) and improved tumor control by radiotherapy in HNSCC modelswithout exacerbating mucositisindicating a widened therapeutic window (146)
Established pharmacological options including acamprosate, naltrexone, and nalmefene remain the evidence-based first-line treatments
This Policy applies to information we collect (1) on this Website and (2) in email, text, and other electronic messages between You and this Website
Jan 17 1997;40(2):137-145
Mosenzon O, Del Prato S, Schechter M, Leiter LA, Ceriello A, DeFronzo RA, et al